Become A Featured Company

Medical Marijuana Inc.’s HempMeds® Draws Attention of United Nations

Ryan Allway

November 2nd, 2017

Exclusive, News, Top News

Cannabidiol (CBD), the main ingredient in Medical Marijuana Inc.’s (OTC Pink: MJNA) products, has been growing in popularity due to its tremendous potential to treat many serious medical conditions. In fact, the cannabinoid has shown promise in treating everything from arthritis to antibiotic resistant infections to schizophrenia. The problem is that regulators still treat CBD like its psychoactive cousin – tetrahydrocannabinol (THC) – which produces a “high” for users.

Medical Marijuana Inc. has made tremendous progress challenging this assertion with the launch of CBD oil products in countries around the world. But recently, an invitation to speak to the United Nations at the World Health Organization could open the doors to marketing CBD as a supplement rather than as a prescription drug.

Building a Global Brand

Medical Marijuana Inc.’s HempMeds® subsidiary has developed leading CBD products under the Real Scientific Hemp Oil – or RSHO™ – brand name. As a full-spectrum, complete CBD hemp oil that contains between 10% and 30% CBD content, the product has quickly become a leading source of medical-grade CBD oil for patients in need around the world, including Brazil, Mexico, Puerto Rico, and throughout the United States.

HempMeds Mexico is the first company to provide Mexican citizens with access to medical products derived from cannabis (THC-free hemp CBD) after the Health Department of Mexico, COFEPRIS, issued the country’s first-ever import permits for Real Scientific Hemp Oil-X™ – or RSHO-X™, in early 2016. The company has made similar breakthroughs in Brazil, where it became the first company to import CBD oil into the country.

In Mexico, the company’s products have also been used in clinical trials evaluating the efficacy of CBD in treating several conditions. One study found that RSHO-X-5000 reduced motor seizures for 84% of patients with Lennox Gastaut Syndrome – a severe form of childhood encephalopathies with high seizure frequency, progressive cognitive impairment, and antiepileptic drug resistance. And, 17% of patients reported no seizures at all.

Validation from the UN

Medical Marijuana Inc. recently announced that HempMeds® Mexico Executive Raul Elizalde has been invited to speak on behalf of the family of companies to the United Nations at the World Health Organization’s International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs in Geneva, Switzerland on November 6, 2017. Elizalde has become a world renowned expert and advocate of CBD therapeutics.

Elizalde will speak to international leaders about his daughter’s personal experience with CBD and urge them to not consider CBD psychoactive and not schedule it as a drug. In addition, he will emphasize the U.S. Ninth Circuit Court ruling that exempted the non-psychoactive parts of the hemp plant from the Controlled Substances Act. He will also present research findings from CBD hemp oil studies on children conducted in Mexico.

“We are honored and excited to speak to United Nations leaders on a global stage about CBD as a supplement aimed to maintain and improve the wellbeing of millions,” said Medical Marijuana Inc. CEO Dr. Stuart Titus in a press release. “We hope to bring light to the many benefits of CBD and convince decision-makers that CBD in its natural botanical state, derived from hemp, should be classified as a supplement.”

Looking Ahead

Medical Marijuana Inc. (OTC Pink: MJNA) is uniquely qualified to capitalize on the growing market for CBD oils and related supplements. In addition to its global presence and growing revenue, international regulatory bodies have recognized its expertise and it could be on the verge of helping change laws around the world to help patients in need.

For more information, visit the company’s website or CannabisFN’s company profile.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading